Overview
Primary interstitial lung disease specific to adulthood (Orphanet code 264740) is a broad grouping category encompassing a heterogeneous collection of rare lung disorders that primarily manifest in adult patients and are characterized by inflammation and/or fibrosis of the lung interstitium — the tissue and space surrounding the air sacs (alveoli) of the lungs. These conditions affect the pulmonary system, leading to progressive scarring or thickening of lung tissue that impairs gas exchange. This category includes entities such as idiopathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP), cryptogenic organizing pneumonia (COP), desquamative interstitial pneumonia (DIP), respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), lymphoid interstitial pneumonia (LIP), and acute interstitial pneumonia (AIP), among others. Key symptoms common across these conditions include progressive exertional dyspnea (shortness of breath with activity), persistent dry cough, fatigue, and in advanced stages, cyanosis and digital clubbing. High-resolution computed tomography (HRCT) of the chest and sometimes surgical lung biopsy are essential for diagnosis. Pulmonary function testing typically reveals a restrictive pattern with reduced diffusing capacity for carbon monoxide (DLCO). The treatment landscape varies considerably depending on the specific subtype. For idiopathic pulmonary fibrosis, antifibrotic agents such as pirfenidone and nintedanib have been shown to slow disease progression. For inflammatory subtypes such as NSIP or COP, corticosteroids and immunosuppressive therapies may be effective. Supportive care including supplemental oxygen, pulmonary rehabilitation, and in severe cases, lung transplantation, are important components of management. Because this Orphanet entry represents a classification group rather than a single disease entity, clinical features, prognosis, and treatment responses are highly variable across the individual conditions within this category.
Also known as:
Variable
Can be inherited in different ways depending on the underlying gene
Adult
Begins in adulthood (age 18 or older)
Treatments
No FDA-approved treatments are currently listed for Primary interstitial lung disease specific to adulthood.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Primary interstitial lung disease specific to adulthood at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Primary interstitial lung disease specific to adulthood.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Primary interstitial lung disease specific to adulthood.
Community
No community posts yet. Be the first to share your experience with Primary interstitial lung disease specific to adulthood.
Start the conversation →Latest news about Primary interstitial lung disease specific to adulthood
No recent news articles for Primary interstitial lung disease specific to adulthood.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Primary interstitial lung disease specific to adulthood
What is Primary interstitial lung disease specific to adulthood?
Primary interstitial lung disease specific to adulthood (Orphanet code 264740) is a broad grouping category encompassing a heterogeneous collection of rare lung disorders that primarily manifest in adult patients and are characterized by inflammation and/or fibrosis of the lung interstitium — the tissue and space surrounding the air sacs (alveoli) of the lungs. These conditions affect the pulmonary system, leading to progressive scarring or thickening of lung tissue that impairs gas exchange. This category includes entities such as idiopathic pulmonary fibrosis (IPF), nonspecific interstitial
At what age does Primary interstitial lung disease specific to adulthood typically begin?
Typical onset of Primary interstitial lung disease specific to adulthood is adult. Age of onset can vary across affected individuals.